von Willebrand factor antigen: a biomarker for severe pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura?

被引:1
|
作者
Davidesko, Sharon [1 ,8 ]
Pikovsky, Oleg [2 ,3 ]
Al-Athamen, Kayed [3 ]
Hackmon, Rinat [4 ]
Erez, Offer [1 ,5 ]
Miodownik, Shayna [6 ]
Rabinovich, Anat [7 ]
机构
[1] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Dept Obstet & Gynecol, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Fac Hlth Sci,Transfus Med Inst, Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Fac Hlth Sci,Hematol Inst, Beer Sheva, Israel
[4] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Maternal Fetal Med Div, Portland, OR USA
[5] Wayne State Univ, Hutzel Womens Hosp, Sch Med, Dept Obstet & Gynecol, Detroit, MI USA
[6] Ben Gurion Univ Negev, Fac Hlth Sci, Med Sch Int Hlth, Beer Sheva, Israel
[7] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Fac Hlth Sci,Hematol Inst,Thrombosis & Hemostasis, Beer Sheva, Israel
[8] B Soroka Univ, Med Ctr, Dept Gynecol & Obstet, POB 151, IL-8410100 Beer Sheva, Israel
关键词
fetal growth restriction; hereditary thrombotic thrombocytopenic purpura; preeclampsia; preterm birth; severe obstetric morbidity; UPSHAW-SCHULMAN SYNDROME; RECOMBINANT ADAMTS13; MORTALITY;
D O I
10.1016/j.jtha.2023.02.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hereditary thrombotic thrombocytopenic purpura (hTTP) is associated with severe obstetric morbidity (SOM) during pregnancy. Treatment with fresh frozen plasma (FFP) mitigates the risk in some women, but others respond poorly and continue to suffer obstetric complications.Objectives: To determine a possible association between SOM and elevated nonpregnant von Willebrand factor (NPVWF) antigen levels in women with hTTP and whether the latter can predict the response to FFP transfusion.Methods: This was a cohort-based study of women with hTTP due to homozygous c.3772delA mutation of ADAMTS-13 who had pregnancies both with and without FFP treatment. Occurrences of SOM were determined from medical records. Generalized estimated equation logistic regressions and receiver operating characteristic curve analysis determined the NPVWF antigen levels associated with the development of SOM.Results: Fourteen women with hTTP had 71 pregnancies; of which 17 (24%) culminated in pregnancy loss and 32 (45%) were complicated by SOM. FFP transfusions were administered in 32 (45%) of the pregnancies. Treated women had decreased SOM (28% vs 72%, p < .001) and preterm thrombotic thrombocytopenic purpura exacerbations (18% vs 82%, p < .001) and higher median NPVWF antigen levels than those of women with uncomplicated pregnancies (p = .018). Among the treated women, median NPVWF antigen levels were higher in those with SOM than in those without SOM (225% vs 165%, p = .047). Logistic regression models demonstrated a significant 2-way associ-ation between elevated NPVWF antigen levels (for SOM, odds ratio, 1.08; 95% CI, 1.001-1.165; p = .046) and SOM (for elevated NPVWF antigen levels, odds ratio, 1.6; 95% CI, 1.329-1.925; p < .001). The receiver operating characteristic curve analysis demonstrated that an NPVWF antigen level of 195% had 75% sensitivity and 72% specificity for SOM. Conclusion: Elevated NPVWF antigen levels are associated with SOM in women with hTTP. Women with levels >195% may benefit from increased surveillance and more intensive FFP treatment during pregnancy.
引用
收藏
页码:1623 / 1629
页数:7
相关论文
共 9 条
  • [1] ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
    Zheng, X. Long
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 211 - 225
  • [2] The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications
    von Krogh, Anne-Sophie
    Hovinga, Johanna A. Kremer
    Tjonnfjord, Geir E.
    Ringen, Ingrid M.
    Laemmle, Bernhard
    Waage, Anders
    Quist-Paulsen, Petter
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) : 1180 - 1183
  • [3] HEMATOLOGIC COMPLICATIONS IN PREGNANCY How I treat thrombotic thrombocytopenic purpura in pregnancy
    Ferrari, Barbara
    Peyvandi, Flora
    BLOOD, 2020, 136 (19) : 2125 - 2132
  • [4] Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case? control study
    Ferrari, Barbara
    Maino, Alberto
    Lotta, Luca A.
    Artoni, Andrea
    Pontiggia, Silvia
    Trisolini, Silvia M.
    Malato, Alessandra
    Rosendaal, Frits R.
    Peyvandi, Flora
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9 : 193
  • [5] Thrombotic thrombocytopenic purpura and severe preeclampsia: a clinical overlap during pregnancy and a possible coexistence
    Dap, Matthieu
    Romiti, Justine
    Dolenc, Berengere
    Morel, Olivier
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2022, 51 (07)
  • [6] A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura
    Jilma-Stohlawetz, Petra
    Gilbert, James C.
    Gorczyca, Monika E.
    Knoebl, Paul
    Jilma, Bernd
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) : 539 - 547
  • [7] Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy
    McMinn, JR
    George, JN
    JOURNAL OF CLINICAL APHERESIS, 2001, 16 (04) : 202 - 209
  • [8] Case of maternal and fetal deaths due to severe congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) during pregnancy
    Tanaka, Hirokazu
    Tenkumo, Chiaki
    Mori, Nobuhiro
    Kokame, Koichi
    Fujimura, Yoshihiro
    Hata, Toshiyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2014, 40 (01) : 247 - 249
  • [9] High sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Pregnancy-Onset Thrombotic Thrombocytopenic Purpura
    Beranger, Nicolas
    Tsatsaris, Vassilis
    Coppo, Paul
    Veyradier, Agnes
    Joly, Berangere S.
    HYPERTENSION, 2023, 80 (09) : E140 - E142